BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 11485406)

  • 21. Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.
    Rao M; Bray M; Alving CR; Jahrling P; Matyas GR
    J Virol; 2002 Sep; 76(18):9176-85. PubMed ID: 12186901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.
    Warfield KL; Olinger G; Deal EM; Swenson DL; Bailey M; Negley DL; Hart MK; Bavari S
    J Immunol; 2005 Jul; 175(2):1184-91. PubMed ID: 16002721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice.
    Patel A; Zhang Y; Croyle M; Tran K; Gray M; Strong J; Feldmann H; Wilson JM; Kobinger GP
    J Infect Dis; 2007 Nov; 196 Suppl 2():S413-20. PubMed ID: 17940978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of continuous human B-cell epitopes in the VP35, VP40, nucleoprotein and glycoprotein of Ebola virus.
    Becquart P; Mahlakõiv T; Nkoghe D; Leroy EM
    PLoS One; 2014; 9(6):e96360. PubMed ID: 24914933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.
    Matassov D; Marzi A; Latham T; Xu R; Ota-Setlik A; Feldmann F; Geisbert JB; Mire CE; Hamm S; Nowak B; Egan MA; Geisbert TW; Eldridge JH; Feldmann H; Clarke DK
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S443-51. PubMed ID: 26109675
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological reactivity of baculovirus-expressed Ebola virus VP35 and nucleoproteins.
    Groen J; van den Hoogen BG; Burghoorn-Maas CP; Fooks AR; Burton J; Clegg CJ; Zeller H; Osterhaus AD
    Microbes Infect; 2003 Apr; 5(5):379-85. PubMed ID: 12737993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever.
    Jones SM; Stroher U; Fernando L; Qiu X; Alimonti J; Melito P; Bray M; Klenk HD; Feldmann H
    J Infect Dis; 2007 Nov; 196 Suppl 2():S404-12. PubMed ID: 17940977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein.
    Martins K; Carra JH; Cooper CL; Kwilas SA; Robinson CG; Shurtleff AC; Schokman RD; Kuehl KA; Wells JB; Steffens JT; van Tongeren SA; Hooper JW; Bavari S
    Viral Immunol; 2015 Feb; 28(1):62-70. PubMed ID: 25514232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
    Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Virology. New vaccine and treatment excite Ebola researchers.
    Enserink M
    Science; 2003 Nov; 302(5648):1141-2. PubMed ID: 14615510
    [No Abstract]   [Full Text] [Related]  

  • 32. Different Temporal Effects of Ebola Virus VP35 and VP24 Proteins on Global Gene Expression in Human Dendritic Cells.
    Ilinykh PA; Lubaki NM; Widen SG; Renn LA; Theisen TC; Rabin RL; Wood TG; Bukreyev A
    J Virol; 2015 Aug; 89(15):7567-83. PubMed ID: 25972536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein.
    Rodriguez-Carreno MP; Nelson MS; Botten J; Smith-Nixon K; Buchmeier MJ; Whitton JL
    Virology; 2005 Apr; 335(1):87-98. PubMed ID: 15823608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.
    Feng Y; Li C; Hu P; Wang Q; Zheng X; Zhao Y; Shi Y; Yang S; Yi C; Feng Y; Wu C; Qu L; Xu W; Li Y; Sun C; Gao FG; Xia X; Feng L; Chen L
    Emerg Microbes Infect; 2018 Jun; 7(1):101. PubMed ID: 29872043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication.
    Hartman AL; Dover JE; Towner JS; Nichol ST
    J Virol; 2006 Jul; 80(13):6430-40. PubMed ID: 16775331
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses.
    Sharpe S; Fooks A; Lee J; Hayes K; Clegg C; Cranage M
    Virology; 2002 Feb; 293(2):210-6. PubMed ID: 11886240
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge.
    Bukreyev A; Yang L; Zaki SR; Shieh WJ; Rollin PE; Murphy BR; Collins PL; Sanchez A
    J Virol; 2006 Mar; 80(5):2267-79. PubMed ID: 16474134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus.
    Hartman AL; Bird BH; Towner JS; Antoniadou ZA; Zaki SR; Nichol ST
    J Virol; 2008 Mar; 82(6):2699-704. PubMed ID: 18199658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults.
    Ledgerwood JE; Costner P; Desai N; Holman L; Enama ME; Yamshchikov G; Mulangu S; Hu Z; Andrews CA; Sheets RA; Koup RA; Roederer M; Bailer R; Mascola JR; Pau MG; Sullivan NJ; Goudsmit J; Nabel GJ; Graham BS;
    Vaccine; 2010 Dec; 29(2):304-13. PubMed ID: 21034824
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A replicating cytomegalovirus-based vaccine encoding a single Ebola virus nucleoprotein CTL epitope confers protection against Ebola virus.
    Tsuda Y; Caposio P; Parkins CJ; Botto S; Messaoudi I; Cicin-Sain L; Feldmann H; Jarvis MA
    PLoS Negl Trop Dis; 2011 Aug; 5(8):e1275. PubMed ID: 21858240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.